SeekingAlpha · Aug 9, 2026
Alger Dynamic Opportunities Fund Q2 2026 Portfolio Update
Class A shares of the Alger Dynamic Opportunities Fund outperformed the S&P 500 Index during the second quarter of 2026. Read more here.
AO
NYSE · AORT
Artivion, Inc.
Healthcare · Medical - Devices
$28.08
Up+$0.10 (+0.36%)
Updated Aug 23, 2026, 4:23 AM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.84B
- P/E ratio
- 187.45
- Dividend yield
- 0.00%
- 52-week range
- $19.16 – $39.66
- Volume
- 485.22K
- Avg. volume
- 384.16K
Price performance
AORT price history
1M range · 20 trading sessions · Daily adjusted prices
AORT closed at $28.08 after 20 trading sessions, up 7.59% for the selected period.
- Last close
- $28.08
- Period change
- +7.59%
- Period low
- $26.10
- Period high
- $29.14
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $27.86 | $28.605 | $27.82 | $28.08 | 485.22K |
| Aug 20, 2026 | $28.49 | $29.01 | $27.77 | $27.98 | 819.36K |
| Aug 19, 2026 | $29.33 | $30.14 | $28.80 | $28.82 | 679.12K |
| Aug 18, 2026 | $28.80 | $29.98 | $28.62 | $28.90 | 846.92K |
| Aug 17, 2026 | $28.73 | $29.065 | $28.285 | $28.32 | 496.15K |
| Aug 14, 2026 | $28.84 | $29.24 | $28.27 | $29.14 | 837.92K |
| Aug 13, 2026 | $28.38 | $28.77 | $28.055 | $28.41 | 774.6K |
| Aug 12, 2026 | $27.95 | $29.335 | $27.73 | $28.64 | 758.95K |
| Aug 11, 2026 | $26.26 | $28.66 | $26.26 | $28.39 | 884.61K |
| Aug 10, 2026 | $26.83 | $27.31 | $26.21 | $26.31 | 728.09K |
| Aug 7, 2026 | $26.90 | $28.265 | $26.725 | $27.12 | 1.08M |
| Aug 6, 2026 | $26.56 | $27.82 | $26.31 | $26.57 | 1.14M |
| Aug 5, 2026 | $26.77 | $27.32 | $25.7875 | $26.17 | 964.01K |
| Aug 4, 2026 | $27.28 | $27.73 | $26.70 | $26.90 | 572.94K |
| Aug 3, 2026 | $27.35 | $28.29 | $27.17 | $27.47 | 831.42K |
| Jul 31, 2026 | $27.21 | $27.56 | $26.61 | $26.83 | 614.65K |
| Jul 30, 2026 | $27.45 | $28.015 | $27.2601 | $27.67 | 712.73K |
| Jul 29, 2026 | $27.43 | $28.03 | $27.28 | $27.55 | 764.14K |
| Jul 28, 2026 | $26.60 | $27.89 | $26.555 | $27.01 | 510.73K |
| Jul 27, 2026 | $25.67 | $26.3785 | $25.56 | $26.10 | 427.6K |
Latest AORT news
The latest Smart Investors Daily articles mentioning AORT.
Stock researchCompany · Overview
AORT research
Overview
Company profile and research snapshot.
Company profile
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $47.50
- Implied upside
- —
- Analysts
- 13
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 18, 2026 | Canaccord Genuity | Buy | — |
| Jul 20, 2026 | Needham | Buy | — |
| Jun 16, 2026 | Canaccord Genuity | Buy | — |
| May 8, 2026 | Citizens | Market Outperform | — |
| May 8, 2026 | Needham | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 7, 2026
Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript
Artivion, Inc. (AORT) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsJames Mackin - Chairman, President & CEOLance Berry - EVP,...
SeekingAlpha · Aug 7, 2026
Artivion, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-07. The following slide deck was published by Artivion, Inc.
Benzinga · Aug 6, 2026
Artivion Affirms FY2026 Sales Guidance of $480.000M-$496.000M vs $486.232M Est
Artivion (NYSE:AORT) affirms FY2026 sales outlook from $480.000 million-$496.000 million to $480.000 million-$496.000 million vs $486.232 million estimate.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
